SINOVAC COVID-19 Vaccine Approved for Use in Children 6 Months and Older in Chile

August 25, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Pública, ISP), with the collaboration and recommendation of the Vaccine Evaluation Expert Committee, approved the age range extension for the use of the Company's COVID-19 vaccine CoronaVac in Chile to 6-months and older. The recommended schedule for this age group is two doses with an interval of 14-18 days.

In 2021, SINOVAC initiated an international, multi-center, case-driven, randomized, double-blind, placebo-controlled Phase III clinical trial in South Africa, Chile, Malaysia, the Philippines, and Kenya, investigating the immunogenicity, safety and efficacy of CoronoVac in children and adolescents from 6 months to 17 years of age. Study results demonstrated good safety and immunogenicity for children 6 to 35-months of age.

By now, CoronaVac has been granted for use for minors in 14 countries including Indonesia, Thailand, Brazil, Chile, Colombia, etc. A total of more than 260 million doses of CoronaVac have been administered, providing protection to more than 130 million minors around the world.

About SINOVAC

Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.

The COVID-19 vaccine, CoronaVac^®, has been approved for use in more than 60 countries and regions worldwide. The Healive^®, hepatitis A vaccine, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive^®, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1^®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu^®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.

Contact:

Sinovac Biotech Ltd.

PR Team

pr@sinovac.com

ICR Inc.

Bill Zima

U.S.: 1-646-308-1707

william.zima@icrinc.com